TrialAssure has released ANONYMIZE 3.0, a significant upgrade to its flagship product that leverages machine learning and artificial intelligence to automate the anonymization of clinical data. This advancement addresses critical industry needs by enabling pharmaceutical companies to share information confidently while protecting patient privacy and corporate secrets. The new version expands support for diverse document types, including emails and Microsoft Office files, while improving the user interface and risk assessment tools. Beyond pharmaceuticals, the underlying technology is now available through the TRUSANO.AI platform, serving government, legal, and financial sectors. This expansion is particularly relevant for entities managing Freedom of Information Act requests, as the system drastically reduces processing times and backlogs. By automating redaction and masking, organizations can enhance transparency and protect commercially confidential information more efficiently than manual methods allow. This development is crucial for open_data advocates because it solves a major barrier to data sharing: privacy preservation. As regulations increasingly demand transparency, automated anonymization tools provide the technical pathway to release valuable datasets without compromising individual rights. By making data sharing safer and more scalable, such technologies facilitate the responsible openness required for scientific progress and public accountability.
Source: biopharmadive.comPublished on 2024-04-02
Related news
- Google to delete or anonymize billions of data points to settle Chrome lawsuit
- AI giants like OpenAI and Anthropic are scrambling to get their hands on enough data to train models
- Augusta County, facing flood of FOIA requests, throwing more money at the problem
- Australia's burnout economy crashes productivity, living standards